

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Terrance L. Geiger

Serial No. 10/568,235

Filed: February 14, 2006

For: Chimeric Receptors With  
Disrupted Dileucine Motifs

Art Unit: 1646

Examiner: Zachary C. Howard

Atty Docket: SJ-03-0016A

**RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENT**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

In response to the restriction requirement dated November 9, 2007 issued for the referenced application, applicants hereby elect claim group I, claims 1-10 and 12-19, for further prosecution. Applicants note that the inventive aspect of the claimed invention is the recognition of an advantage conferred by disruption of dileucine motifs in chimeric receptors.

In response to the election of species requirement applied to this claim group, applicants hereby elect the SEQ ID No. 8 (SRRNRLL) as the species of dileucine motif and human CD28 as the species of CD28 protein. Claims encompassing the elected species are claims 1-10 and 12-19.

In accordance with election of species practice, Applicants understand that the elected dileucine motif and CD28 protein will be used as a guide to initiate examination. Once the claims are determined to be allowable with respect to this dileucine motif and CD28 protein, another dileucine motif and CD28 protein will be selected for examination in this same application. This will be followed by continued selections until the examiner is satisfied that the genus is allowable.

No fee is believed to be required for consideration of this submission. If applicants are incorrect and a fee is required the Commissioner is hereby authorized to charge such fee to Deposit Account No. 501968.

Respectfully submitted,



James Scott Elmer  
Attorney for Applicant  
Registration No. 36,129

St. Jude Children's Research Hospital  
332 North Lauderdale  
Memphis, TN 38105-2794  
Telephone: 901-495-2756

Date: December 7, 2007